Biogen and Eisai have reported that their therapy, Aduhelm (aducanumab-avwa), substantially reduced plasma p-tau181 in two Phase III EMERGE and ENGAGE clinical trials.

A monoclonal antibody, Aducanumab-avwa acts against amyloid-beta.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest data from nearly 7,000 plasma samples obtained from more than 1,800 subjects in the Phase III trials showed that there is a statistically significant link between the decline in plasma p-tau, as well as reduced cognitive and functional decline in Alzheimer’s.

In addition, the decline in plasma p-tau181 was linked to reductions in amyloid-beta plaque.

Biogen noted that Aduhelm reduced tau pathology as assessed by plasma p-tau18, which is an Alzheimer’s-specific biomarker, versus placebo in the latest assessment.

In addition, Aduhelm had a greater impact at increased doses and for a longer period of time.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The statistically significant link between change in plasma p-tau181 and amyloid-beta plaque reduction also demonstrates the impact of Aduhelm treatment on the two crucial pathological features of the disease.

Biogen Research and Development head Alfred Sandrock said: “We now have robust and concordant data that Aduhelm has an effect on two core defining pathologies of Alzheimer’s disease, and substantial evidence of treatment correlation between changes in plasma p-tau181 and the slowing of disease progression.

“We are committed to continuing to generate data, and we believe these new findings can help inform treatment choice and advance Alzheimer’s research including in diagnosis and disease monitoring.”

In July 2021, the companies revealed the design of a real-world observational Phase IV ICARE AD-US study of Aduhelm in Alzheimer’s disease.

This study is intended to obtain real-world data on the long-term efficacy and safety of a 100mg/mL injectable dose of Aduhelm.